Hutchmed (China) Limited

AGM Information • Apr 27, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5371W

Hutchison China Meditech Limited

27 April 2016

Results of Annual General Meeting

London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly passed.  The poll results of the resolutions were as follows:

				Number of Votes (%)*
Resolutions				For	Against	Withheld#
1	To consider and adopt the statement of audited accounts and the reports of the directors and independent auditor for the year ended December 31, 2015.			50,155,497 (99.9994%)	280 (0.0006%)	21,058
2	(a) To re-elect Mr Simon To as a director.			49,077,310 (99.8719%)	62,950 (0.1281%)	1,036,575
	(b) To re-elect Mr Christian Hogg as a director.			50,155,427 (99.9576%)	21,250 (0.0424%)	158
	(c) To re-elect Mr Christian Salbaing as a director.			50,155,397 (99.9576%)	21,280 (0.0424%)	158
	(d) To re-elect Ms Edith Shih as a director.			50,155,647 (99.9581%)	21,030 (0.0419%)	158
	(e) To re-elect Mr Christopher Nash as a director.			49,116,261 (97.8866%)	1,060,416 (2.1134%)	158
	(f) To re-elect Mr Michael Howell as a director.			49,055,784 (97.7661%)	1,120,892 (2.2339%)	159
	(g) To re-elect Professor Christopher Huang as a director.			49,116,211            (97.8865%)	1,060,466 (2.1135%)	158
3	To re-appoint PricewaterhouseCoopers as the auditor of Chi-Med and authorise the board of directors to fix the auditor's remuneration.			50,111,239 (99.9111%)	44,588 (0.0889%)	21,008
4	Ordinary Resolution No. 4(A)	:	To grant a general mandate to the directors of Chi-Med to issue additional shares.	50,174,133 (99.9953%)	2,371 (0.0047%)	331
	Special Resolution No. 4(B)	:	To disapply pre-emption rights.	47,883,975 (95.5053%)	2,253,552 (4.4947%)	39,108
	Ordinary Resolution No. 4(C)	:	To grant a general mandate to the directors of Chi-Med to repurchase shares of Chi-Med.	50,108,396 (99.8639%)	68,288 (0.1361%)	151

*  Percentages rounded to 4 decimal places

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and againsta resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 60,639,926, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolution proposed at the AGM. 

Ends

Contact

Investor Inquiries
Christian Hogg, CEO	+852 2121 8200
International Media Inquiries
Anthony Carlisle, Citigate Dewe Rogerson	+44 7973 611 888 (Mobile) [email protected]
U.S. Based Media Inquiries
Brad Miles, BMC Communications	+1 (917) 570 7340 (Mobile) [email protected]
Susan Duffy, BMC Communications	+1 (917) 499 8887 (Mobile) [email protected]
Investor Relations
Jillian Connell, The Trout Group	+1 (646) 378 2956 [email protected]
David Dible, Citigate Dewe Rogerson	+44 20 7638 9571 +44 7967 566 919 (Mobile) [email protected]
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts	+44 (20) 7886 2500

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMSEFFEWFMSEFL